---
title: Effects of Involvement in a Group-based Creative Expression Program on Psychotropic Drug Use in Persons With Dementia
nct_id: NCT01382693
overall_status: COMPLETED
phase: NA
sponsor: Milton S. Hershey Medical Center
study_type: INTERVENTIONAL
primary_condition: Dementia
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT01382693.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT01382693"
ct_last_update_post_date: 2012-07-04
last_seen_at: "2026-05-12T07:26:19.585Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Effects of Involvement in a Group-based Creative Expression Program on Psychotropic Drug Use in Persons With Dementia

**Official Title:** Effects of Involvement in a Group-based Creative Expression Program on Psychotropic Drug Use in Persons With Dementia in Long-term Care: a Cluster-randomized Pilot Study

**NCT ID:** [NCT01382693](https://clinicaltrials.gov/study/NCT01382693)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 20
- **Lead Sponsor:** Milton S. Hershey Medical Center
- **Conditions:** Dementia
- **Start Date:** 2011-06
- **Completion Date:** 2011-09
- **CT.gov Last Update:** 2012-07-04

## Brief Summary

This project, a small-scale pilot study, will attempt to determine if involvement in a group-based creative expression program may correlate with a reduction in use of psychotropic drugs for persons with dementia.

## Detailed Description

The study site has two skilled-nursing dementia Special Care Units. One unit will serve as a control with residents receiving the standard care activity program. The other unit will receive the standard care activity program as well as the TimeSlips storytelling program (two hour-long sessions per week for six weeks). The behavioral symptoms and psychotropic drug usage for both cohorts will be studied for eight months, the first four months with no intervention and the last four months with or without the six-week TimeSlips intervention.

## Eligibility

- **Minimum age:** 60 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* residence in one of two dementia special-care skilled nursing units at the study site
* clinical diagnosis of dementia
```

## Arms

- **TimeSlips group storytelling program** (EXPERIMENTAL)
- **Standard care activity program** (ACTIVE_COMPARATOR)

## Interventions

- **TimeSlips** (BEHAVIORAL) — TimeSlips is a group-based creative storytelling program for people with dementia. The intervention will be held twice a week for six weeks, in hour-long sessions.
- **Standard care activity program** (BEHAVIORAL) — Standard-of-care activities for the study site's skilled-nursing dementia Special Care Units.

## Primary Outcomes

- **Rates of psychotropic drug prescriptions for study participants.** _(time frame: eight months)_

## Secondary Outcomes

- **Mood and behavior patterns** _(time frame: eight months)_

## Locations (1)

- Landis Homes, Lititz, Pennsylvania, United States

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.landis homes|lititz|pennsylvania|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT01382693.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT01382693*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*